Generic placeholder image

The Natural Products Journal

Editor-in-Chief

ISSN (Print): 2210-3155
ISSN (Online): 2210-3163

Research Article

Scaphechinus mirabilis Extract Effectively Inhibits the Proliferation of BPH-1 and LNCaP Prostate Epithelial Cells

Author(s): Kyung-Hyun Kim, Geum-Lan Hong , Shanika Karunasagara and Ju-Young Jung*

Volume 12, Issue 2, 2022

Published on: 05 July, 2021

Article ID: e030621193849 Pages: 7

DOI: 10.2174/2210315511666210603153637

Price: $65

Abstract

Background: Benign Prostatic Hyperplasia (BPH) is an age-related disease characterized by progressive proliferation of prostate stromal and epithelial cells. While the precise etiology of BPH is still not clear, the proliferation of epithelial cells has been implicated in the development of the disease. Scaphechinus mirabilis (S. mirabilis) is a marine species belonging to the order Clypeasteroida, which contains flat, burrowing sea urchins.

Objectives: This study examined the effects of S. mirabilis extract on the proliferation of BPH-1 and LNCaP prostate epithelial cells.

Methods: BPH-1 and LNCaP cells were cultured and treated with S. mirabilis extract (50, 100, and 200 μg/ml). The viability of cells treated with S. mirabilis extract was determined by the MTT assay.

Results: Proliferation of BPH-1 and testosterone-induced LNCaP cells was inhibited by treatment with S. mirabilis extract. S. mirabilis extract suppressed the expression of androgen-related proteins, such as androgen receptor, prostate-specific antigen, and 5α-reductase 2. S. mirabilis extract inhibited testosterone-induced proliferation. Moreover, S. mirabilis extract induced apoptotic responses by regulating the expression of caspase-9, Bcl-2, and Bax.

Conclusion: These findings suggest that S. mirabilis extract abrogated the expression of androgen- related proteins by inducing apoptotic responses, which could be valuable for the design of new therapeutic agents for the treatment of BPH.

Keywords: Prostate epithelial cell, Scaphechinus mirabilis, LNCaP, BPH-1, cell proliferation, apoptosis.

Graphical Abstract
[1]
Verze, P.; Cai, T.; Lorenzetti, S. The role of the prostate in male fertility, health and disease. Nat. Rev. Urol., 2016, 13(7), 379-386.
[http://dx.doi.org/10.1038/nrurol.2016.89] [PMID: 27245504]
[2]
Roehrborn, C.G. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med. Clin. North Am., 2011, 95(1), 87-100.
[http://dx.doi.org/10.1016/j.mcna.2010.08.013] [PMID: 21095413]
[3]
D’Elia, C.; Cerruto, M.A.; Cioffi, A.; Novella, G.; Cavalleri, S.; Artibani, W. Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy. Mol. Clin. Oncol., 2014, 2(6), 1145-1149.
[http://dx.doi.org/10.3892/mco.2014.370] [PMID: 25279213]
[4]
Kyprianou, N.; Tu, H.; Jacobs, S.C. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum. Pathol., 1996, 27(7), 668-675.
[http://dx.doi.org/10.1016/S0046-8177(96)90396-2] [PMID: 8698310]
[5]
Carson, C., III; Rittmaster, R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology, 2003, 61(4)(Suppl. 1), 2-7.
[http://dx.doi.org/10.1016/S0090-4295(03)00045-1] [PMID: 12657354]
[6]
Salam, A.; Mohammed, F.H.; Anil K., Philip; Mays, Abd-Allateef; Emad, Yousif Role of aromatase and anastrozole in cancer treatment. Int. J. Pharm. Sci. Rev. Res., 2016, 40(1), 5.
[7]
Corona, G.; Tirabassi, G.; Santi, D.; Maseroli, E.; Gacci, M.; Dicuio, M.; Sforza, A.; Mannucci, E.; Maggi, M. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: A comprehensive review and meta-analysis. Andrology, 2017, 5(4), 671-678.
[http://dx.doi.org/10.1111/andr.12353] [PMID: 28453908]
[8]
Nickel, J.C.; Gilling, P.; Tammela, T.L.; Morrill, B.; Wilson, T.H.; Rittmaster, R.S. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: The enlarged prostate international comparator study (EPICS). BJU Int., 2011, 108(3), 388-394.
[http://dx.doi.org/10.1111/j.1464-410X.2011.10195.x] [PMID: 21631695]
[9]
Kominami, T.; Takata, H. Cellular basis of gastrulation in the sand dollar scaphechinus mirabilis. Biol. Bull., 2000, 199(3), 287-297.
[http://dx.doi.org/10.2307/1543185] [PMID: 11147709]
[10]
Vickman, R.E.; Franco, O.E.; Moline, D.C.; Vander Griend, D.J.; Thumbikat, P.; Hayward, S.W. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian J. Urol., 2020, 7(3), 191-202.
[http://dx.doi.org/10.1016/j.ajur.2019.10.003] [PMID: 32742923]
[11]
Ho, C.K.; Habib, F.K. Estrogen and androgen signaling in the pathogenesis of BPH. Nat. Rev. Urol., 2011, 8(1), 29-41.
[http://dx.doi.org/10.1038/nrurol.2010.207] [PMID: 21228820]
[12]
Labrie, F.; Luu-The, V.; Lin, S.X.; Simard, J.; Labrie, C.; El-Alfy, M.; Pelletier, G.; Bélanger, A. Intracrinology: Role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 2000, 25(1), 1-16.
[http://dx.doi.org/10.1677/jme.0.0250001] [PMID: 10915214]
[13]
Guo, Z.; Yang, X.; Sun, F.; Jiang, R.; Linn, D.E.; Chen, H.; Chen, H.; Kong, X.; Melamed, J.; Tepper, C.G.; Kung, H.J.; Brodie, A.M.; Edwards, J.; Qiu, Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res., 2009, 69(6), 2305-2313.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-3795] [PMID: 19244107]
[14]
Wilson, C.M.; McPhaul, M.J. A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol. Cell. Endocrinol., 1996, 120(1), 51-57.
[http://dx.doi.org/10.1016/0303-7207(96)03819-1] [PMID: 8809738]
[15]
Hassan, F.; El-Hiti, G.A.; Abd-Allateef, M.; Yousif, E. Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells. Saudi Med. J., 2017, 38(4), 359-365.
[http://dx.doi.org/10.15537/smj.2017.4.17061] [PMID: 28397941]
[16]
Kim, E.H.; Brockman, J.A.; Andriole, G.L. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J. Urol., 2018, 5(1), 28-32.
[http://dx.doi.org/10.1016/j.ajur.2017.11.005] [PMID: 29379733]
[17]
Lee, J.Y.; Cho, K.S. Effects of 5-alpha reductase inhibitors: New insights on benefits and harms. Curr. Opin. Urol., 2018, 28(3), 288-293.
[http://dx.doi.org/10.1097/MOU.0000000000000497] [PMID: 29528971]
[18]
Thompson, C.B. Apoptosis in the pathogenesis and treatment of disease. Science, 1995, 267(5203), 1456-1462.
[http://dx.doi.org/10.1126/science.7878464] [PMID: 7878464]
[19]
Darzynkiewicz, Z.; Bedner, E.; Smolewski, P. Flow cytometry in analysis of cell cycle and apoptosis. Semin. Hematol., 2001, 38(2), 179-193.
[http://dx.doi.org/10.1016/S0037-1963(01)90051-4] [PMID: 11309699]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy